MediciNova acquires two blood clotting agents
MN-447 and MN-462 are anti-clotting agents that represent novel approaches to blood clot formation and are expected to treat a variety of thrombotic disorders. Both agents have demonstrated
Ultragenyx Pharmaceutical has received accelerated approval from the US Food and Drug Administration (FDA) for its gene therapy, Genglycos (pariglasgene brecaparvovec-opnr), to treat glycogen storage disease type Ia (GSDIa).